Six months after announcing a first wave of cost cuts, Novavax is instituting another round, looking to shave off a further $300 million in spending with more layoffs on the way.

在宣布第一波成本削减六个月后，Novavax正在进行另一轮削减，希望通过更多裁员，进一步削减3亿美元的支出。

The drug developer, which is still sprinting to catch up to Pfizer and Moderna in the COVID-19 vaccine race, announced the news as part of its third-quarter earnings report Thursday. The company said in a statement that exact decisions about the cuts have not been agreed but that some layoffs will likely be included..

这家药物开发公司周四宣布了这一消息，作为其第三季度盈利报告的一部分。该公司仍在快速追赶辉瑞（Pfizer）和摩德纳（Moderna），以在新型冠状病毒（COVID-19）疫苗竞赛中赶上辉瑞（Moderna）。该公司在一份声明中表示，关于裁员的确切决定尚未达成一致，但可能会包括一些裁员。。

“We have not yet finalized decisions about these cost reductions but expect it will include reduction of external spend, focused headcount reductions, and a review of our facilities,” the biotech told Fierce. “In all of our actions, we will prioritize preserving the key capabilities we need to be successful.”.

“我们有 尚未就这些成本降低做出最终决定 但希望它会 包括 减少外部支出，集中人员 生物技术公司告诉《猛兽》杂志。“在我们的所有行动中，我们将优先保留取得成功所需的关键能力。”。

Roughly two-thirds of the new cuts will be found in R&D and SG&A, while the other $100 million will come from shavings to supply chain-related expenses, CFO Jim Kelly said on an earnings call. CEO John Jacobs echoed that the plan is to make substantive cuts, not accounting tweaks.

首席财务官吉姆·凯利（JimKelly）在一次财报电话会议上表示，大约三分之二的新削减将用于研发和销售及管理，而另外一亿美元将来自刨花和供应链相关费用。首席执行官约翰·雅各布斯（JohnJacobs）也表示，该计划是要进行实质性削减，而不是会计调整。

“We’re confident we can make the real cuts, as Jim said, not by accounting function, but by reducing scope and scale,” Jacobs told analysts on the call. The previously announced cost reductions spurred layoffs to 25% of employees, but it’s unclear how many new jobs are now on the chopping block.

雅各布斯在电话会议上告诉分析师：“正如吉姆所说，我们有信心实现真正的削减，不是通过会计职能，而是通过缩小范围和规模。”。先前宣布的成本削减刺激了25%的员工裁员，但目前尚不清楚有多少新工作岗位即将被裁掉。

Novavax’s updated full-year 2023 guidance now expects $1.2 million in R&D and SG&A expenses, a nearly 30% reduction compared to full-year 2022. The full 2024 guidance is now set to be below $750 million, down by more than a quarter from the original projection for that year.

Novavax最新发布的2023年全年指南预计研发和销售及管理费用将达到120万美元，比2022年全年减少近30%。2024年的全部指导目标现在定在7.5亿美元以下，比当年的原始预测下降了四分之一以上。

The moves come as Novavax is a few weeks into its first full year on the U.S. COVID-19 vaccine market, though it’s still operating under emergency use authorization as opposed to full approval.

此举正值Novavax进入美国新型冠状病毒肺炎疫苗市场的第一个完整年份几周之际，尽管它仍在紧急使用授权下运行，而不是完全批准。

Moderna recently had to write off $1.3 billion due to “excess and obsolete” vaccine stock while Pfizer was left with $5.6 billion in COVID-related inventory write-offs and other expenses.

由于“过剩和过时”的疫苗库存，Moderna最近不得不注销13亿美元，而辉瑞公司则剩下56亿美元与新型冠状病毒相关的库存注销和其他费用。